Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks
出版年份 2023 全文链接
标题
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks
作者
关键词
-
出版物
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-10-31
DOI
10.1111/apt.17764
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Lipid profile, lipid ratios, apolipoproteins, and risk of cardiometabolic multimorbidity in men: The Kuopio Ischaemic Heart Disease Risk Factor Study
- (2022) Behnam Tajik et al. LIPIDS
- Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study
- (2022) Eiichi Ogawa et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Coronary computed tomography angiography evaluation of plaque morphology and its relationship to HDL and total cholesterol to HDL ratio
- (2022) Venkat S. Manubolu et al. Journal of Clinical Lipidology
- New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
- (2021) Dan Atar et al. ATHEROSCLEROSIS
- Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching from Tenofovir Disoproxil Fumarate
- (2021) Kwan Soo Byun et al. Clinical Gastroenterology and Hepatology
- Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCDID Cohort
- (2020) Aoife Lacey et al. AIDS
- Dyslipidaemia after switch to tenofovir alafenamide (TAF)‐based cART regimens in a cohort of HIV‐positive patients: what clinical relevance?
- (2020) L Gazzola et al. HIV MEDICINE
- The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
- (2020) Nicola Squillace et al. Drug Design Development and Therapy
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2019) Scott M. Grundy et al. CIRCULATION
- Chronic hepatitis B and metabolic risk factors: A call for rigorous longitudinal studies
- (2019) Wai-Kay Seto WORLD JOURNAL OF GASTROENTEROLOGY
- Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study
- (2019) Renato Quispe et al. European Journal of Preventive Cardiology
- Atherosclerotic Cardiovascular Disease Risk Prediction in Disaggregated Asian and Hispanic Subgroups Using Electronic Health Records
- (2019) Fatima Rodriguez et al. Journal of the American Heart Association
- Lipid changes due to tenofovir alafenamide are reversible by switching back to tenofovir disoproxil fumarate
- (2019) Ana Milinkovic et al. AIDS
- Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting
- (2019) Kai Juhani Kauppinen et al. AIDS PATIENT CARE AND STDS
- Changes in Body Mass Index and Atherosclerotic Disease Risk Score after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
- (2019) Jason J Schafer et al. Open Forum Infectious Diseases
- Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate
- (2019) Gregory D Huhn et al. Open Forum Infectious Diseases
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
- (2018) Norah A. Terrault et al. HEPATOLOGY
- Hepatitis B virus and the risk of coronary heart disease: A comprehensive systematic review and meta-analyses of observational studies
- (2018) Yaqin Wang et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- 96 weeks treatment of tenofovir alafenamide vs . tenofovir disoproxil fumarate for hepatitis B virus infection
- (2018) Kosh Agarwal et al. JOURNAL OF HEPATOLOGY
- Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
- (2018) Purificación Cid‐Silva et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease
- (2018) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study
- (2017) Ming-Whei Yu et al. GASTROENTEROLOGY
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
- (2017) Pietro Lampertico et al. JOURNAL OF HEPATOLOGY
- Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B
- (2016) Lai Wei et al. CURRENT MEDICAL RESEARCH AND OPINION
- Association between hepatitis B and metabolic syndrome: Current state of the art
- (2016) Peter Jarcuska WORLD JOURNAL OF GASTROENTEROLOGY
- The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
- (2015) José R. Santos et al. CLINICAL INFECTIOUS DISEASES
- Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection
- (2015) Kosh Agarwal et al. JOURNAL OF HEPATOLOGY
- Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B - a prospective cohort study with paired transient elastography examinations
- (2014) G. L.-H. Wong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers
- (2013) Álvaro Mena et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection
- (2012) Yu-Tse Tsan et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search